Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial

Documenti analoghi

• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial
  di: Thomas Capozza, et al.
  Pubblicazione: (2025)
• First‐In‐Human, Randomized, Placebo‐Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults
  di: Marcus May, et al.
  Pubblicazione: (2025)
• Evaluation of NaTto Red Yeast Rice on Regulating Blood Lipid (ENTRY) Study: A Multicenter, Double‐Placebo, Double‐Blinded, Randomized Controlled Trial in Chinese Adults
  di: Shufeng Chen, et al.
  Pubblicazione: (2025)
• Safety, Pharmacokinetics, and Immunogenicity of Astegolimab, an Anti‐ST2 Monoclonal Antibody, in Randomized, Phase I Clinical Studies
  di: Wenhui Zhang, et al.
  Pubblicazione: (2025)
• Modulating Placebo Effects in Clinical Trials: Study Team Briefing to Optimize Drug–Placebo Differences
  di: Martin Coenen, et al.
  Pubblicazione: (2025)